Scientists at acib and the University of Natural Resources Vienna develop world’s first continuous purification method for valuable drugs. This will lead to significantly reduced production costs and to cheaper pharmaceuticals that are affordable for non-privileged health care systems.
Imagine a dear relative suffering from cancer – and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly.
Without antibodies we would be at the mercy of pathogens or cancer cells. Therapeutic antibodies are used as passive vaccines, for cancer therapy or for controlling autoimmune diseases such as multiple sclerosis. According to “bccresearch.com” the global market for antibody drugs was worth nearly 70 billion USD in 2014 and should rise to 122 billion USD until 2019.
Two thirds of those molecules are produced biotechnologically using Chinese hamster ovary cells (CHO). Actually the major cost factor for industry is purification using “protein A” affinity chromatography where tens of thousands of liters of culture volume have to be processed annually. About 80 % of the production costs fall upon purification.
Here this new purification method comes into play. Researchers from the Austrian Centre of Industrial Biotechnology (acib) and the University of Natural Resources and Life Sciences Vienna (BOKU) developed the world’s first downstream processing method for recombinant antibodies from clarified CHO cultures. From a technical view, the purification method combines a Calcium-Phosphate flocculation with a subsequent cold ethanol precipitation in a tubular reactor realized as a double-pipe heat exchanger that is operated in counter-current flow.
A feasibility study exemplified by the purification of immune globulin G (IgG) shows that the continuous method can compete with “protein A” affinity chromatography in terms of yield and outperforms chromatography according to the speed of operation. A further advantage is that the operation parameters can be easily transferred from the actually used batch to the continuous approach. In combination with a prior concentration step the new method is perfect for purification of low titer supernatants. “Our method shows great potential as a new platform technology for the pharmaceutical industry”, says Prof. Alois Jungbauer, who is in negotiations with several international companies about building pilot plants.
The Latest on: Drug production
via Google News
The Latest on: Drug production
- Industry Voices—Industry reaction to shortages of lifesaving drugs underscores urgencyon October 30, 2019 at 1:20 pm
In order to stop this behavior, the industry is in dire need of product availability information that could avert stockpiling. Group purchasing organizations (GPOs) can and should help with this.
- Should Adults Be Allowed to Use Any Drug They Choose? A Soho Forum Debateon October 30, 2019 at 1:20 pm
all laws that penalize drug production, distribution, possession, and use should be abolished, along with special "sin" taxes on drugs. Arguing for the affirmative was Sullum, who is the author ...
- Congress, Grappling With Tainted Chinese Drugs, Is Baffled by Lack of FDA Oversight in U.S. Pharmaceutical Supply Chainon October 30, 2019 at 11:50 am
at the lack of oversight the FDA demonstrates over these foreign suppliers—despite the fact that U.S. drug firms are continuously outsourcing their manufacturing needs. "There's a hidden health crisis ...
- Forced Drug Prices Are Not The Answer To Health Care Costson October 30, 2019 at 11:15 am
It was not until domestic oil production increased and consumers purchased more energy efficient cars that ... the secretary of HHS to negotiate prices on the top 250 medicates for which there is no ...
- Global Drug Suppliers Challenge FDA as Safety Fears Riseon October 30, 2019 at 9:54 am
The Food and Drug Administration is encouraging drug companies to invest in new production technologies that could help return some manufacturing to U.S. shores. The U.S. is currently home to only ...
- FDA task force offers suggestions to reduce drug shortageson October 30, 2019 at 9:32 am
It said that “prices rarely rose after shortages began” even though production usually remained below pre-shortage levels, a finding that conflicts with anecdotal evidence often offered by healthcare ...
- Public Drug Testing Sites Are Helping Dealers Prevent Overdoseson October 30, 2019 at 8:42 am
recently co-authored an academic paper which examined the role of drug dealers in reducing drug-related harms via checking their product. “We know that a couple of suppliers who are active in ...
- Biogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.on October 30, 2019 at 7:36 am
... shocked investors on the day of its earnings call last week by announcing that it planned to submit its Alzheimer’s drug aducanumab for Food and Drug Administration approval. The product had ...
- HIV Drugs Market Growth Predictions, Leading Players : Bristol-Myers Squibb, Gilead Sciences and GlaxoSmithKlineon October 30, 2019 at 6:42 am
Oct 30, 2019 (WiredRelease via COMTEX) -- A Precise market analysis on Global HIV Drugs Product Market | Know Up Trends And More About Industry Tycoons, Emerging Growth Factors, Opportunities, Top Key ...
- Ophthalmic Drugs Market By By Drug Class Outlook, Disease Outlook, Dosage Form, Product Type, Geography and Forecast 2019 – 2026on October 30, 2019 at 3:30 am
The study on Ophthalmic Drugs Market provides analysis of China market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes ...
via Bing News